Publication:

Imaging Tumor Vascularity and Response to Anti-Angiogenic Therapy Using Gaussia Luciferase

Loading...
Thumbnail Image

Open/View Files

Date

2016

Published Version

Journal Title

Journal ISSN

Volume Title

Publisher

Nature Publishing Group
The Harvard community has made this article openly available. Please share how this access benefits you.

Research Projects

Organizational Units

Journal Issue

Citation

Kantar, Rami S., Ghazal Lashgari, Elie I. Tabet, Grant K. Lewandrowski, Litia A. Carvalho, and Bakhos A. Tannous. 2016. “Imaging Tumor Vascularity and Response to Anti-Angiogenic Therapy Using Gaussia Luciferase.” Scientific Reports 6 (1): 26353. doi:10.1038/srep26353. http://dx.doi.org/10.1038/srep26353.

Abstract

We developed a novel approach to assess tumor vascularity using recombinant Gaussia luciferase (rGluc) protein and bioluminescence imaging. Upon intravenous injection of rGluc followed by its substrate coelenterazine, non-invasive visualization of tumor vascularity by bioluminescence imaging was possible. We applied this method for longitudinal monitoring of tumor vascularity in response to the anti-angiogenic drug tivozanib. This simple and sensitive method could be extended to image blood vessels/vasculature in many different fields.

Description

Research Data

Keywords

Terms of Use

This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service

Endorsement

Review

Supplemented By

Related Stories